welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement


Eli Lilly and Company and Precision BioSciences, Inc. announced a research collaboration and exclusive license agreement to utilize Precision’s proprietary ARCUS® genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets.

Genome editing technologies enable precise editing of the DNA of a living organism, opening up the possibility of correcting genetic problems at their source. ARCUS is a unique, proprietary, and versatile genome editing platform with attributes including specificity, ability to make a variety of efficient edits (knock-in, knock-out, and repair), and small size, thereby enabling a range of therapeutic editing. The platform is derived from a natural genome-editing enzyme called I-CreI, a homing endonuclease that can be optimized to control for potency and specificity.

Lilly And Precision BioSciences Announce Genome Editing Research Collaboration And License Agreement